Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Review
. 2021 Jun;70(6):651-663.
doi: 10.1007/s00011-021-01470-1. Epub 2021 May 20.

Are chimeric antigen receptor T cells (CAR-T cells) the future in immunotherapy for autoimmune diseases?

Yeison Santamaria-Alza  1 , Gloria Vasquez  2
Affiliations
Review

Are chimeric antigen receptor T cells (CAR-T cells) the future in immunotherapy for autoimmune diseases?

Yeison Santamaria-Alza et al. Inflamm Res. 2021 Jun.

Abstract

Objective: CAR-T cell therapy has revolutionized the treatment of oncological diseases, and potential uses in autoimmune diseases have recently been described. The review aims to integrate the available data on treatment with CAR-T cells, emphasizing autoimmune diseases, to determine therapeutic advances and their possible future clinical applicability in autoimmunity.

Materials and methods: A search was performed in PubMed with the keywords "Chimeric Antigen Receptor" and "CART cell". The documents of interest were selected, and a critical review of the information was carried out.

Results: In the treatment of autoimmune diseases, in preclinical models, three different cellular strategies have been used, which include Chimeric antigen receptor T cells, Chimeric autoantibody receptor T cells, and Chimeric antigen receptor in regulatory T lymphocytes. All three types of therapy have been effective. The potential adverse effects within them, cytokine release syndrome, cellular toxicity and neurotoxicity must always be kept in mind.

Conclusions: Although information in humans is not yet available, preclinical models of CAR-T cells in the treatment of autoimmune diseases show promising results, so that in the future, they may become a useful and effective therapy in the treatment of these pathologies.

Keywords: Autoimmunity; CAR T cell therapy; Chimeric T cell receptors; Immunotherapy; Regulatory T lymphocytes.

PubMed Disclaimer

References

    1. June CH, Sadelain M. Chimeric antigen receptor therapy. N Engl J Med. 2018;379(1):64–73. https://doi.org/10.1056/NEJMra1706169 . - DOI - PubMed - PMC
    1. Maus MV, June CH. Making better chimeric antigen receptors for adoptive T cell therapy. Clin Cancer Res. 2016;22(8):1875–84. https://doi.org/10.1158/1078-0432.CCR-15-1433 . - DOI - PubMed - PMC
    1. Akhavan D, Alizadeh D, Wang D, Weist MR, Shepphird JK, Brown CE. CAR T cells for brain tumors: lessons learned and road ahead. Immunol Rev. 2019;290(1):60–84. https://doi.org/10.1111/imr.12773 . - DOI - PubMed - PMC
    1. Chen B, Zhou M, Zhang H, et al. TREM1/Dap12-based CAR-T cells show potent antitumor activity. Immunotherapy. 2019;11(12):1043–55. https://doi.org/10.2217/imt-2019-0017 . - DOI - PubMed
    1. Heczey A. Alliance of the Titans: an effective combination of a TKI with CAR T cells. Mol Ther. 2019;27(8):1348–9. https://doi.org/10.1016/j.ymthe.2019.07.008 . - DOI - PubMed - PMC

Substances

LinkOut - more resources